Police raid striking doctors' homes, offices, after deadline passes on return-to-work order
Yoon touts improved Japan ties on Independence Movement Day as gateway to 'new world'
DP leader Lee retains ticket to his constituency for April elections
Korean stocks benefit from Zuckerberg's Seoul visit
Tensions loom as doctors plan mass rally in deepening clash over med school quota
[Weekender] Car camping: How solo female campers enjoy outdoors
[EYE] A Buddhist temple where animal spirits find peace
NewJeans, Silica Gel win 3 prizes at KMAs; Beenzino nets album of the year
S. Korea's meat consumption exceeds rice intakes for 2nd year
South Korea publicly orders some doctors who walked off the job back to work
SK to host San Francisco biopharma networking eventBy Jie Ye-eun
Published : Jan. 10, 2023 - 15:09
SK Inc., the investment arm of SK Group, said Tuesday it will co-host a networking event with the group’s biopharmaceutical affiliates including SK biopharmaceuticals and SK pharmteco to expand its global partnerships in the US, the world’s largest bio and pharmaceutical market.
The event, titled “SK Bio Night,” will take place at the Four Seasons Hotel in San Francisco on Wednesday. About 100 executives from some 50 companies -- including SK’s biopharma firms, the group’s global partners and investment companies -- will attend the meeting, the SK officials said.
SK Inc. Vice Chairman Jang Dong-hyun, SK biopharmaceuticals CEO Lee Dong-hoon, SK pharmteco CEO Joerg Ahlgrimm and SK Bio Investment Center head Kim Yeon-tae are set to attend Wednesday’s event. They will present how their companies are building thriving businesses in the global biopharmaceutical sector, according to the SK officials.
“To forge landmark opportunities in key markets like the US and Europe, we wish to build stronger connections with our existing and potential future partners at SK Bio Night,” SK Bio Investment Center's Kim Yeon-tae said.
“We are excited to share our impressive growth trajectory with our global partners and investors.”
While the US and Europe markets account for 95 percent of SK pharmteco’s global customer base, SK Inc. hopes to explore various business partnerships and investment opportunities in the global market through the event.
To enhance competitiveness, SK Inc. has adopted a localization strategy focusing on the development of new small-molecule drugs and the Global Cell and Gene Therapy and Contract Development and Manufacturing Organization (CGT CDMO) business in the US and Europe.
Last year, SK Inc. entered the CGT CDMO business by acquiring France-based Yposkesi through SK pharmteco. SK’s investment arm became the second-largest shareholder of the Center for Breakthrough Medicine this year.
Tensions loom as doctors plan mass rally
S. Korea’s 1st spy satellite sends ‘quality’ images of Pyongyang
Ex-PPP leader to run for seat in less conservative Hwaseong city